Clinical Exome Sequencing (CES)

Clinical Exome Sequencing (CES) is a targeted, high-depth Next-Generation Sequencing (NGS) analysis focused specifically on gene regions with well-established disease associations in medical literature (OMIM/phenotype-associated genes). While Whole Exome Sequencing (WES) captures all protein-coding regions, CES concentrates on clinical relevance, offering higher coverage depth, faster turnaround times, and cost-effective diagnostic yield for routine clinical workflows.

Key Features & Advantages

1. Targeted Diagnostic Power: Focuses exclusively on ~6,000–8,000 disease-associated genes, significantly reducing the burden of Variants of Uncertain Significance (VUS).
2. Superior Coverage Depth: By targeting a refined genomic region, CES achieves extremely high read depth (typically 150x–200x+), minimizing false negatives and enhancing mosaic variant detection.
3. Accelerated Turnaround Time: A more compact dataset streamlines bioinformatics processing and clinical interpretation, delivering actionable results faster.
4. High Diagnostic Yield: Delivers direct diagnostic clarity for symptomatic patients by evaluating all known pathogenic genes simultaneously

Clinical Exome (CES) vs. Whole Exome (WES) Comparison

Clinical Applications

1. Suspected Hereditary Disorders: Diagnostic resolution for clinical phenotypes matching known genetic syndromes.
2. Neurogenetics & Metabolic Disease: Target-rich evaluation for pediatric epilepsy, neuromuscular disorders, and inborn errors of metabolism.
3. Cardiovascular Genetics: Identifying pathogenic variants responsible for inherited cardiomyopathies and channelopathies.
4. Pediatric Phenotypic Diagnostics: Confirming genetic etiologies in complex, multi-system pediatric cases.
5. 
   

The Nucleus Genetics Advantage: Combining phenotype-driven bioinformatics filtering with expert medical genetics curation, we convert raw clinical exome data into precise, physician-ready diagnostic reports.